Buy Thymosin Alpha-1 Canada | TA1 10mg
Janoshik
Batch TA1-CA-26F-10
Buy Thymosin Alpha-1 Canada | TA1 10mg
Thymic Peptide Research Compound
Thymosin Alpha-1 is a peptide studied in laboratory settings for its role in immune system signaling and regulation pathways. Research commonly examines its influence on T-cell activity, cytokine modulation, and broader immune response mechanisms in controlled experimental models.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
Thymosin Alpha-1 is a synthetic peptide analogue of a naturally occurring thymic hormone involved in immune signaling research. It is developed for controlled laboratory investigation within experimental environments.
In scientific literature, Thymosin Alpha-1 is studied in models examining immune cell signaling pathways, cytokine modulation frameworks, and receptor-mediated regulatory systems under in vitro and preclinical research conditions.
Third-party tested for purity, identity, quantity.
Thymosin Alpha-1 is a 28–amino acid peptide derived from prothymosin alpha and has been evaluated in research focused on immune-related signaling systems. Experimental studies examine its interaction with immune cell regulatory pathways and cytokine-associated signaling mechanisms within controlled laboratory environments.
Research publications have explored its receptor interaction dynamics and pathway-level regulatory frameworks under structured study conditions.
Thymosin Alpha-1 was identified during early investigations into thymic hormones and immune system regulation. Subsequent biochemical research isolated active peptide fragments responsible for signaling activity within immune-related pathways.
Over time, synthetic analogues were developed to allow controlled experimental study of thymic peptide signaling systems and immune regulatory frameworks.
Laboratory investigations into Thymosin Alpha-1 have focused on immune cell signaling models, cytokine-associated pathway studies, and receptor-mediated regulatory systems. Research frameworks evaluate peptide interaction within immune signaling environments under controlled in vitro and preclinical conditions.
3 of the 4 areas below are addressed directly by a paper cited on this page.
Immune cell signaling pathway models
Addressed on this page by Binsfeld 2015, Malinda 1998, Liu 2020. The work appeared in Clin Infect Dis. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Binsfeld, M. et al. (2015) — Impact of the immunomodulating peptide thymosin alpha-1 on multiple myeloma and immune recovery after hematopoietic stem cell transplantation.
- Malinda, K.M. et al. (1998) — Thymosin alpha-1 stimulates endothelial cell migration, angiogenesis, and wound healing.
- Liu, Y. et al. (2020) — Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clin Infect Dis 71(16):2150–2157.
Cytokine regulatory framework studies
No paper cited on this page reports on cytokine. This heading marks where Thymosin Alpha-1 is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Thymic peptide interaction research
Addressed on this page by Binsfeld 2015. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Binsfeld, M. et al. (2015) — Impact of the immunomodulating peptide thymosin alpha-1 on multiple myeloma and immune recovery after hematopoietic stem cell transplantation.
Receptor-mediated immune signaling investigations
Addressed on this page by Binsfeld 2015. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Binsfeld, M. et al. (2015) — Impact of the immunomodulating peptide thymosin alpha-1 on multiple myeloma and immune recovery after hematopoietic stem cell transplantation.
The references section of this page cites 4 primary papers published between 1998 and 2023 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Thymosin Alpha-1, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Thymosin Alpha-1 is also referred to as Ta1, thymalfasin.
Approved prescription medicines containing the same active ingredient are sold under the brand name Zadaxin. The material supplied here is not those products and is not interchangeable with them. Those are regulated pharmaceuticals manufactured to a licensed specification and dispensed under medical supervision. This is a research compound, and what is published for it is its measured purity and content per lot.
Thymosin Alpha-1 is commonly described online in connection with stronger immune function and resistance to infection. In the research literature the same compound is filed under immune cell signaling pathway models, cytokine regulatory framework studies and thymic peptide interaction research.
The 4 papers cited on this page, published between 1998 and 2023 describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for Thymosin Alpha-1 is per lot, not per product. The current 10mg lot TA1-CA-26F-10 returned 99.699% purity, 11.64 mg measured, 116.4% of the labelled 10 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is Thymosin Alpha-1; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for Thymosin Alpha-1, this lot measured 116.4% of its labelled 10 mg. Both numbers are published for every lot, whichever way they fall.
The lot code printed on the vial matches the code on the certificate for Thymosin Alpha-1. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy Thymosin Alpha-1 in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Bacteriostatic water in most published protocols
- Format
- Lyophilized powder
Thymosin Alpha-1 is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 28 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial in the strength selected (10mg / Single Vial, 10mg / 5-Pack, 10mg / 10-Pack available), batch-labelled
- The batch-linked Certificate of Analysis for the exact lot shipped
- Discreet outer packaging with no product names on the exterior
- Canada Post Xpress, tracked, typically 1–2 business days from Alberta
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains 10mg of lyophilized Thymosin Alpha-1. Independent third-party testing verifies purity, identity, and net content per batch.
The vial contains only the peptide preparation. Any laboratory materials required for experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
Thymosin alpha-1 stimulates endothelial cell migration, angiogenesis, and wound healing.
PubMedImpact of the immunomodulating peptide thymosin alpha-1 on multiple myeloma and immune recovery after hematopoietic stem cell transplantation.
PubMedThymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clin Infect Dis 71(16):2150–2157.
PubMedA Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection. J Infect Dis 227(11):1255–1265.
PubMedRelated
You May Also Like
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
$60.00
$70.00
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
$35.00
$40.00
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$70.00
This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
$150.00